Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Kaken Pharmaceutical Revenue

Kaken Pharmaceutical had revenue of 30.16B JPY in the quarter ending June 30, 2026, with 59.83% growth. This brings the company's total for the last twelve months to 88.16B, down -6.86% year-over-year. In the fiscal year ending March 31, 2026, Kaken Pharmaceutical had annual revenue of 76.87B, down -18.25%. That makes Kaken Pharmaceutical the 10,600th largest company in the world by revenue and 1,105th in Japan.

• Revenue (ttm): 88.16B
• Revenue Growth: -6.86%
• P/S Ratio: 1.65
• Revenue / Employee: 79.14M
• Employees: 1,114
• Market Cap: 145.41B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Industry 74.33B 96.7%
• Real Estate 2.54B 3.3%

By Geography

Chart

• Japan 64.03B 83.3%
• United States 9.02B 11.7%
• Asia 2.85B 3.7%
• Others 479.00M 0.6%
• North America (excl. United States) 400.00M 0.5%
• Europe 89.00M 0.1%

Fiscal year ended Mar 31, 2026 See the full Kaken Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	76.87B	-17.16B	-18.25%
Mar 31, 2025	94.04B	21.99B	30.52%
Mar 31, 2024	72.04B	-940.00M	-1.29%
Mar 31, 2023	72.98B	-3.05B	-4.01%
Mar 31, 2022	76.03B	1.06B	1.41%

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error